$INFU
InfuSystem Holdings, Inc Stock $infu

$infu Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000162828024015511 Filed on April 10, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$33.70M	$31.77M	$125.8M
YoY Change	6.19%	10.2%	14.44%
Cost Of Revenue	$17.03M	$16.89M	$62.68M
YoY Change	11.36%	32.51%	32.39%
Gross Profit	$16.67M	$14.88M	$63.11M
YoY Change	1.37%	-7.48%	0.86%
Gross Profit Margin	49.46%	46.84%	50.17%
Selling, General & Admin	$14.57M	$13.08M	$58.03M
YoY Change	-2.98%	-10.91%	-0.52%
% of Gross Profit	87.39%	87.92%	91.95%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$3.033M	$3.144M	$11.52M
YoY Change	-1.94%	1.29%	6.0%
% of Gross Profit	18.2%	21.13%	18.25%
Operating Expenses	$14.81M	$13.63M	$59.02M
YoY Change	-2.51%	-9.46%	-3.11%
Operating Profit	$1.855M	$1.250M	$4.088M
YoY Change	48.64%	21.48%	147.16%
Interest Expense	-$484.0K	-$503.0K	$2.170M
YoY Change	-178.06%	18.08%	54.78%
% of Operating Profit	-26.09%	-40.24%	53.08%
Other Income/Expense, Net	-$63.00K	-$20.00K	-$67.00K
YoY Change	-3250.0%	-62.26%	-45.08%
Pretax Income	$1.308M	$727.0K	$1.851M
YoY Change	107.62%	32.18%	1323.85%
Income Tax	$600.0K	$655.0K	$979.0K
% Of Pretax Income	45.87%	90.1%	52.89%
Net Earnings	$717.0K	$72.00K	$872.0K
YoY Change	64.83%	-32.71%	4744.44%
Net Earnings / Revenue	2.13%	0.23%	0.69%
Basic Earnings Per Share	$0.03		$0.04
Diluted Earnings Per Share	$0.03	$0.00	$0.04
COMMON SHARES
Basic Shares Outstanding	21.26M shares	21.18M shares	21.02M shares
Diluted Shares Outstanding	21.71M shares		21.65M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$146.0K	$231.0K	$231.0K
YoY Change	8.96%	40.0%	40.0%
Cash & Equivalents	$146.0K	$231.0K	$231.0K
Short-Term Investments
Other Short-Term Assets	$4.603M	$4.157M	$4.157M
YoY Change	17.54%	42.27%	42.27%
Inventory	$6.839M	$6.402M	$6.402M
Prepaid Expenses
Receivables	$21.33M	$19.83M	$19.83M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$32.91M	$30.62M	$30.62M
YoY Change	14.98%	23.57%	23.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.174M	$4.321M	$49.00M
YoY Change	-3.0%	-1.46%	-3.53%
Goodwill	$3.710M	$3.710M
YoY Change	0.0%	0.0%
Intangibles	$6.951M	$7.446M
YoY Change	-12.48%	-11.74%
Long-Term Investments
YoY Change
Other Assets	$1.334M	$1.581M	$12.14M
YoY Change	8.99%	1876.25%	4.01%
Total Long-Term Assets	$75.61M	$72.30M	$72.30M
YoY Change	2.01%	-3.1%	-3.1%
TOTAL ASSETS
Total Short-Term Assets	$32.91M	$30.62M	$30.62M
Total Long-Term Assets	$75.61M	$72.30M	$72.30M
Total Assets	$108.5M	$102.9M	$102.9M
YoY Change	5.62%	3.55%	3.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.940M	$8.009M	$8.009M
YoY Change	81.35%	-3.98%	-3.98%
Accrued Expenses			$1.474M
YoY Change			65.25%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$15.88M	$15.71M	$15.71M
YoY Change	23.42%	8.61%	8.61%
LONG-TERM LIABILITIES
Long-Term Debt	$34.17M	$29.10M	$29.10M
YoY Change	-5.46%	-12.23%	-12.23%
Other Long-Term Liabilities	$4.995M	$5.799M	$5.799M
YoY Change	31.93%	54.19%	54.19%
Total Long-Term Liabilities	$34.17M	$29.10M	$34.90M
YoY Change	-5.46%	-12.23%	-5.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.88M	$15.71M	$15.71M
Total Long-Term Liabilities	$34.17M	$29.10M	$34.90M
Total Liabilities	$55.04M	$50.61M	$50.61M
YoY Change	4.26%	-1.5%	-1.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$59.30M	-$58.63M
YoY Change	-0.14%	-1.21%
Common Stock	$2.000K	$2.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$53.49M	$52.30M	$52.30M
YoY Change
Total Liabilities & Shareholders Equity	$108.5M	$102.9M	$102.9M
YoY Change	5.62%	3.55%	3.55%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$717.0K	$72.00K	$872.0K
YoY Change	64.83%	-32.71%	4744.44%
Depreciation, Depletion And Amortization	$3.033M	$3.144M	$11.52M
YoY Change	-1.94%	1.29%	6.0%
Cash From Operating Activities	$2.309M	$4.658M	$11.22M
YoY Change	-5.83%	2.01%	-35.93%
INVESTING ACTIVITIES
Capital Expenditures	$7.640M	$1.998M	$1.024M
YoY Change	138.53%	-50.7%	4.28%
Acquisitions
YoY Change
Other Investing Activities	$944.0K	$954.0K	$4.383M
YoY Change	9.26%	-4.7%	21.82%
Cash From Investing Activities	-$6.696M	-$1.044M	-$6.734M
YoY Change	186.28%	-65.79%	-41.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$153.0K
YoY Change			-97.2%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.711M	-3.544M	-$4.423M
YoY Change	-1679.15%	107.01%	-27.01%
NET CHANGE
Cash From Operating Activities	2.309M	4.658M	$11.22M
Cash From Investing Activities	-6.696M	-1.044M	-$6.734M
Cash From Financing Activities	3.711M	-3.544M	-$4.423M
Net Change In Cash	-676.0K	70.00K	$66.00K
YoY Change	454.1%	-135.35%	-414.29%
FREE CASH FLOW
Cash From Operating Activities	$2.309M	$4.658M	$11.22M
Capital Expenditures	$7.640M	$1.998M	$1.024M
Free Cash Flow	-$5.331M	$2.660M	$10.20M
YoY Change	609.85%	418.52%	-38.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-35020
CY2023	dei	Entity Registrant Name EntityRegistrantName	INFUSYSTEM HOLDINGS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-3341405
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3851 West Hamlin Road
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Rochester Hills
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48309
CY2023	dei	City Area Code CityAreaCode	(248)
CY2023	dei	Local Phone Number LocalPhoneNumber	291-1210
CY2023	dei	Trading Symbol TradingSymbol	INFU
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	990000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2494000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4262000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12259000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10777000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40677000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	58906000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	55716000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	4088000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	2820000	usd
CY2023	us-gaap	Interest Expense InterestExpense	2170000	usd
CY2022	us-gaap	Interest Expense InterestExpense	1402000	usd
CY2021	us-gaap	Interest Expense InterestExpense	1377000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-67000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-122000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-186000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	130000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1257000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-163000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21024382	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20648818	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21646079	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21547306	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22049659	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	872000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent	355000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent	-122000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent	388000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent	87000	usd
CY2023Q4	infu	Medical Equipment In Rental Service Net Of Accumulated Depreciation MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation	34928000	usd
CY2023	infu	Depreciation Expense Related To Medical Equipment DepreciationExpenseRelatedToMedicalEquipment	10400000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5947000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4321000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9295000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4910000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4385000	usd
CY2023	us-gaap	Depreciation Nonproduction DepreciationNonproduction	1100000	usd
CY2022	us-gaap	Depreciation Nonproduction DepreciationNonproduction	1100000	usd
CY2021	us-gaap	Depreciation Nonproduction DepreciationNonproduction	900000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	2000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	29439000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	29439000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12654000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45377000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	44153000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	59021000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	1654000	usd
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	560000	usd
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001337013
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	us-gaap	Operating Lease Income Comprehensive Income Extensible List OperatingLeaseIncomeComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#Revenues
CY2023	us-gaap	Sales Type Lease Income Comprehensive Income Extensible List SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#Revenues
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	190572924	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21264695	shares
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2022	dei	Auditor Firm AuditorFirmId	243
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Detroit, Michigan
CY2022	dei	Auditor Name AuditorName	BDO USA, LLP
CY2022	dei	Auditor Location AuditorLocation	Troy, Michigan
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	231000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	165000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19830000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16871000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6402000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4821000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4157000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2922000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	30620000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	24779000	usd
CY2023Q4	infu	Medical Equipment Held For Sale Or Rental MedicalEquipmentHeldForSaleOrRental	3049000	usd
CY2022Q4	infu	Medical Equipment Held For Sale Or Rental MedicalEquipmentHeldForSaleOrRental	2790000	usd
CY2023Q4	infu	Medical Equipment In Rental Service Net Of Accumulated Depreciation MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation	34928000	usd
CY2022Q4	infu	Medical Equipment In Rental Service Net Of Accumulated Depreciation MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation	39450000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4321000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4385000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3710000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3710000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7446000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8436000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6703000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4168000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	9115000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	9625000	usd
CY2023Q4	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	1442000	usd
CY2022Q4	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	1965000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1581000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	80000	usd
CY2023Q4	us-gaap	Assets Assets	102915000	usd
CY2022Q4	us-gaap	Assets Assets	99388000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8009000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8341000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7704000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6126000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15713000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14467000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	29101000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33157000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5799000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3761000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	50613000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	51385000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21196851	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21196851	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20781977	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20781977	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	109837000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	105856000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1088000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1489000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58625000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59344000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	52302000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	48003000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	102915000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	99388000	usd
CY2023	us-gaap	Revenues Revenues	125785000	usd
CY2022	us-gaap	Revenues Revenues	109914000	usd
CY2021	us-gaap	Revenues Revenues	102382000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	62676000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	49354000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	43846000	usd
CY2023	us-gaap	Gross Profit GrossProfit	63109000	usd
CY2022	us-gaap	Gross Profit GrossProfit	60560000	usd
CY2021	us-gaap	Gross Profit GrossProfit	58536000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1420000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent	-523000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent	1609000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-401000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1221000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	268000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	471000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1239000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1688000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	40752000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	812000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6404000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	348000	usd
CY2021	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	268000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1420000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48272000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	891000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3825000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	428000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1193000	usd
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	5459000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1221000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	48003000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	618000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4074000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	446000	usd
CY2023	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	153000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-401000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	872000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	52302000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	872000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1420000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-261000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	87000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	77000	usd
CY2023	us-gaap	Depreciation Depreciation	11518000	usd
CY2022	us-gaap	Depreciation Depreciation	10866000	usd
CY2021	us-gaap	Depreciation Depreciation	10363000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1726000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1933000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1029000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	2887000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	2183000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	2545000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	990000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2494000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4262000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	120000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	73000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	151000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4074000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3825000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	6404000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	633000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	19000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-153000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2363000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1153000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-829000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1581000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	882000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	864000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1235000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	387000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	133000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2798000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	135000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	161000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	2415000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	2942000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-2363000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	11223000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	17517000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	18316000	usd
CY2023	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	usd
CY2022	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	usd
CY2021	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	7976000	usd
CY2023	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	10093000	usd
CY2022	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	14094000	usd
CY2021	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	15676000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1024000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	982000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	980000	usd
CY2023	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	4383000	usd
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	3598000	usd
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	3317000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6734000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11478000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21315000	usd
CY2023	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	55499000	usd
CY2022	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	42035000	usd
CY2021	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	81660000	usd
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	51552000	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	42022000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	229000	usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	750000	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	5459000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	560000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1158000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1193000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1172000	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1064000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1355000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1124000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4423000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6060000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6463000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	66000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9462000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	186000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9648000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	186000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2052000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1310000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1113000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	213000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	153000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	171000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	249000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1902000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1590000	usd
CY2023	infu	Noncash Or Part Noncash Acquisition Contingent Consideration Arrangements Change In Amount Of Contingent Consideration NoncashOrPartNoncashAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsideration	0	usd
CY2022	infu	Noncash Or Part Noncash Acquisition Contingent Consideration Arrangements Change In Amount Of Contingent Consideration NoncashOrPartNoncashAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsideration	0	usd
CY2021	infu	Noncash Or Part Noncash Acquisition Contingent Consideration Arrangements Change In Amount Of Contingent Consideration NoncashOrPartNoncashAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsideration	750000	usd
CY2023	infu	Noncash Activities Proceeds From Stock Plans NoncashActivitiesProceedsFromStockPlans	0	usd
CY2022	infu	Noncash Activities Proceeds From Stock Plans NoncashActivitiesProceedsFromStockPlans	0	usd
CY2021	infu	Noncash Activities Proceeds From Stock Plans NoncashActivitiesProceedsFromStockPlans	36000	usd
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt">Basis of Presentation and Nature of Operations</span><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem Holdings, Inc. and its consolidated subsidiaries (collectively, the “Company”) are a leading national provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from seven locations in the United States ("U.S.") and Canada. The Company provides products and services to hospitals, oncology practices and facilities and other alternate site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. InfuSystem, Inc. and First Biomedical, Inc. are both operating subsidiaries of the Company.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s core service is supplying electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer, pain management and other disease states. The majority of the Company’s pumps are electronic infusion pumps. Smiths Medical, Inc., a division of ICU Medical, Inc., supplied more than 60% of the ambulatory pumps purchased by the Company in 2023. The Company has a supply agreement in place with this supplier. Certain “spot” purchases are made on the open market subject to individual negotiation. The Company also supplies Negative Pressure Wound Therapy (“NPWT”) medical equipment, as well as related disposables and ancillary supplies.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company sells or rents new and pre-owned pole-mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings including home care and home infusion providers, skilled nursing and acute care facilities, pain centers and others.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Company’s ambulatory infusion pump management service.</span></div>The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”)
CY2023	infu	Number Of Locations NumberOfLocations	7	location
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgements that affect amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ from those estimates.</span></div>
CY2023Q4	infu	Number Of Financial Institutions NumberOfFinancialInstitutions	2	financial_institution
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	600000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1100000	usd
CY2023	infu	Medical Equipment In Rental Services Useful Life MedicalEquipmentInRentalServicesUsefulLife	P7Y
CY2023Q4	infu	Medical Equipment In Rental Services Reserve MedicalEquipmentInRentalServicesReserve	2100000	usd
CY2022Q4	infu	Medical Equipment In Rental Services Reserve MedicalEquipmentInRentalServicesReserve	2300000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	0	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	0	usd
CY2023	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	100000	usd
CY2022	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	100000	usd
CY2021	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	1600000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P8Y
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Concentration</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company had contracts with nearly 820 and 800 third-party payer networks, respectively. Material terms of contracts with third-party payer organizations are typically a pre-negotiated fee schedule rate or a then-current proprietary fee schedule rate for equipment and supplies provided. The majority of these contracts generally provide for a term of one year, with automatic one-year renewals, unless the Company or the contracted payer elect not to renew. The Company also contracts with various other third-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of its Medicare patients and numerous other insurance carriers. No single payer or customer represented more than 10% of the Company's net revenue in 2023, 2022 or 2021.</span></div>
CY2023Q4	infu	Number Of Contracts With Third Parties NumberOfContractsWithThirdParties	820	network
CY2022Q4	infu	Number Of Contracts With Third Parties NumberOfContractsWithThirdParties	800	network
CY2023	infu	Term Of Contract TermOfContract	P1Y
CY2023	infu	Term Of Renewal TermOfRenewal	P1Y
CY2021	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	3500000	shares
CY2023	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	0	shares
CY2022	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	0	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	872000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1420000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21024382	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20648818	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20519958	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	621697	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	898488	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1529701	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21646079	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21547306	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22049659	shares
CY2023	us-gaap	Revenues Revenues	125785000	usd
CY2022	us-gaap	Revenues Revenues	109914000	usd
CY2021	us-gaap	Revenues Revenues	102382000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19830000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16871000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15405000	usd
CY2023Q4	infu	Contract Assets ContractAssets	1271000	usd
CY2022Q4	infu	Contract Assets ContractAssets	360000	usd
CY2021Q4	infu	Contract Assets ContractAssets	0	usd
CY2023Q4	infu	Medical Equipment Held For Sale Or Rental Gross MedicalEquipmentHeldForSaleOrRentalGross	3081000	usd
CY2022Q4	infu	Medical Equipment Held For Sale Or Rental Gross MedicalEquipmentHeldForSaleOrRentalGross	2802000	usd
CY2023Q4	infu	Medical Equipment Held For Sale Or Rental Reserve MedicalEquipmentHeldForSaleOrRentalReserve	32000	usd
CY2022Q4	infu	Medical Equipment Held For Sale Or Rental Reserve MedicalEquipmentHeldForSaleOrRentalReserve	12000	usd
CY2023Q4	infu	Medical Equipment Held For Sale Or Rental MedicalEquipmentHeldForSaleOrRental	3049000	usd
CY2022Q4	infu	Medical Equipment Held For Sale Or Rental MedicalEquipmentHeldForSaleOrRental	2790000	usd
CY2023Q4	infu	Medical Equipment In Rental Services Gross MedicalEquipmentInRentalServicesGross	96298000	usd
CY2022Q4	infu	Medical Equipment In Rental Services Gross MedicalEquipmentInRentalServicesGross	99163000	usd
CY2023Q4	infu	Medical Equipment In Rental Services Reserve MedicalEquipmentInRentalServicesReserve	2126000	usd
CY2022Q4	infu	Medical Equipment In Rental Services Reserve MedicalEquipmentInRentalServicesReserve	2270000	usd
CY2023Q4	infu	Medical Equipment In Rental Services Accumulated Depreciation MedicalEquipmentInRentalServicesAccumulatedDepreciation	59244000	usd
CY2022Q4	infu	Medical Equipment In Rental Services Accumulated Depreciation MedicalEquipmentInRentalServicesAccumulatedDepreciation	57443000	usd
CY2022Q4	infu	Medical Equipment In Rental Service Net Of Accumulated Depreciation MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation	39450000	usd
CY2023Q4	infu	Medical Equipment Net MedicalEquipmentNet	37977000	usd
CY2022Q4	infu	Medical Equipment Net MedicalEquipmentNet	42240000	usd
CY2022	infu	Depreciation Expense Related To Medical Equipment DepreciationExpenseRelatedToMedicalEquipment	9800000	usd
CY2021	infu	Depreciation Expense Related To Medical Equipment DepreciationExpenseRelatedToMedicalEquipment	9400000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10268000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	2000000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	2000000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	2000000	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	52572000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	45126000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7446000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	52572000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	44136000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8436000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2500000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4300000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	990000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	810000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	525000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	471000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	348000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2302000	usd
CY2023Q4	infu	Unamortized Debt Issuance Expense Current UnamortizedDebtIssuanceExpenseCurrent	0	usd
CY2023Q4	infu	Unamortized Debt Issuance Expense Noncurrent UnamortizedDebtIssuanceExpenseNoncurrent	338000	usd
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	338000	usd
CY2022Q4	infu	Unamortized Debt Issuance Expense Current UnamortizedDebtIssuanceExpenseCurrent	0	usd
CY2022Q4	infu	Unamortized Debt Issuance Expense Noncurrent UnamortizedDebtIssuanceExpenseNoncurrent	227000	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	227000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	29101000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	29101000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33157000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	33157000	usd
CY2023	us-gaap	Interest Expense InterestExpense	2200000	usd
CY2022	us-gaap	Interest Expense InterestExpense	1400000	usd
CY2021	us-gaap	Interest Expense InterestExpense	1400000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1566000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	63000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1033000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	285000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	67000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	224000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1851000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	130000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1257000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	568000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-44000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-150000	usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	568000	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-44000	usd
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-150000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	245000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	99000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	167000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	65000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	65000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3000	usd
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	310000	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	164000	usd
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	164000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	101000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-8000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-177000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	979000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	112000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-163000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	389000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	27000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	264000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	245000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	130000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	130000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	16000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	12000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	260000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	58000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-462000	usd
CY2023	infu	Effective Income Tax Rate Reconciliation Tax Credits Amount EffectiveIncomeTaxRateReconciliationTaxCreditsAmount	-39000	usd
CY2022	infu	Effective Income Tax Rate Reconciliation Tax Credits Amount EffectiveIncomeTaxRateReconciliationTaxCreditsAmount	79000	usd
CY2021	infu	Effective Income Tax Rate Reconciliation Tax Credits Amount EffectiveIncomeTaxRateReconciliationTaxCreditsAmount	34000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	30000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-28000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-73000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	979000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	112000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-163000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	3318000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	2603000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1812000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1668000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8680000	usd
CY2023Q4	infu	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	1864000	usd
CY2022Q4	infu	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	1210000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	792000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	552000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	626000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	639000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	555000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	555000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	102000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	141000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	616000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	432000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16085000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16480000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4131000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4505000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	768000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	800000	usd
CY2023Q4	infu	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	1718000	usd
CY2022Q4	infu	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	1075000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Derivatives DeferredTaxLiabilitiesDerivatives	353000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Derivatives DeferredTaxLiabilitiesDerivatives	475000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6970000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6855000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	9115000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	9625000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1504000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1333000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1316000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	336000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	301000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	243000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1840000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1634000	usd
CY2021	us-gaap	Lease Cost LeaseCost	1559000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1441000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1241000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1271000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3356000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	926000	usd
CY2023	infu	Increases To Right Of Use Assets Resulting From Lease Modifications IncreasesToRightOfUseAssetsResultingFromLeaseModifications	552000	usd
CY2022	infu	Increases To Right Of Use Assets Resulting From Lease Modifications IncreasesToRightOfUseAssetsResultingFromLeaseModifications	1050000	usd
CY2021	infu	Increases To Right Of Use Assets Resulting From Lease Modifications IncreasesToRightOfUseAssetsResultingFromLeaseModifications	0	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.077
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.071
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1796000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1837000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1654000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1478000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1429000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2424000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10618000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3345000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7273000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5800000	usd
CY2023	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	23797000	usd
CY2022	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	24413000	usd
CY2021	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	21678000	usd
CY2023	us-gaap	Sales Type Lease Lease Income SalesTypeLeaseLeaseIncome	3250000	usd
CY2022	us-gaap	Sales Type Lease Lease Income SalesTypeLeaseLeaseIncome	72000	usd
CY2021	us-gaap	Sales Type Lease Lease Income SalesTypeLeaseLeaseIncome	0	usd
CY2023	us-gaap	Lease Income LeaseIncome	27047000	usd
CY2022	us-gaap	Lease Income LeaseIncome	24485000	usd
CY2021	us-gaap	Lease Income LeaseIncome	21678000	usd
CY2023Q4	us-gaap	Sales Type Lease Lease Receivable SalesTypeLeaseLeaseReceivable	2583000	usd
CY2022Q4	us-gaap	Sales Type Lease Lease Receivable SalesTypeLeaseLeaseReceivable	45000	usd
CY2023Q4	us-gaap	Sales Type Lease Net Investment In Lease SalesTypeLeaseNetInvestmentInLease	2583000	usd
CY2022Q4	us-gaap	Sales Type Lease Net Investment In Lease SalesTypeLeaseNetInvestmentInLease	45000	usd
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths	1238000	usd
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears	1217000	usd
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears	539000	usd
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived	2994000	usd
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Undiscounted Excess Amount SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount	411000	usd
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable SalesTypeAndDirectFinancingLeasesLeaseReceivable	2583000	usd
CY2023	infu	Share Based Compensation Arrangement By Share Based Payment Award Options Reduction Ratio ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio	1
CY2023	infu	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Reduction Ratio ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio	2
CY2023	us-gaap	Restricted Stock Expense RestrictedStockExpense	2584000	usd
CY2022	us-gaap	Restricted Stock Expense RestrictedStockExpense	2683000	usd
CY2021	us-gaap	Restricted Stock Expense RestrictedStockExpense	4491000	usd
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1490000	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1142000	usd
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1913000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4074000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3825000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6404000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1045000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	857000	usd
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	2234000	usd
CY2023	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	115979	shares
CY2022	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	136718	shares
CY2021	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	57067	shares
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2023	us-gaap	Employee Stock Ownership Plan Esop Shares Contributed To Esop EmployeeStockOwnershipPlanESOPSharesContributedToESOP	300000	shares
CY2014Q2	us-gaap	Employee Stock Ownership Plan Esop Shares Contributed To Esop EmployeeStockOwnershipPlanESOPSharesContributedToESOP	200000	shares
CY2014Q2	infu	Employee Stock Purchase Plan Discount Rate EmployeeStockPurchasePlanDiscountRate	0.15
CY2014Q2	infu	Employee Stock Purchase Plan Offering Period EmployeeStockPurchasePlanOfferingPeriod	P6M
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	350000	shares
CY2014Q2	infu	Employee Stock Ownership Plan Espp Purchase Per Employee Maximum EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum	25000	usd
CY2023Q4	infu	Stock Issued During Period Shares Employee Stock Ownership Plan Number Of Remaining Shares Available For Future Issuance StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance	323756	shares
CY2023	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	179595	usd
CY2022	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	229064	usd
CY2021	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	173561	usd
CY2023	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	71623	shares
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	60673	shares
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	31624	shares
CY2023	infu	Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased	7.32
CY2022	infu	Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased	11.53
CY2021	infu	Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased	16.95
CY2021Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	20000000	usd
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	6200000	usd
	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	553149	shares
CY2023	infu	Net Revenues External NetRevenuesExternal	125785000	usd
CY2023	infu	Net Revenues Internal NetRevenuesInternal	0	usd
CY2023	us-gaap	Revenues Revenues	125785000	usd
CY2023	us-gaap	Gross Profit GrossProfit	63109000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	59021000	usd
CY2023	us-gaap	Interest Expense InterestExpense	2170000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-67000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1851000	usd
CY2023Q4	us-gaap	Assets Assets	102915000	usd
CY2023	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	10093000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12508000	usd
CY2022	infu	Net Revenues External NetRevenuesExternal	109914000	usd
CY2022	infu	Net Revenues Internal NetRevenuesInternal	0	usd
CY2022	us-gaap	Revenues Revenues	109914000	usd
CY2022	us-gaap	Gross Profit GrossProfit	60560000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	58906000	usd
CY2022	us-gaap	Interest Expense InterestExpense	1402000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-122000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	130000	usd
CY2022Q4	us-gaap	Assets Assets	99388000	usd
CY2022	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	14094000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13360000	usd
CY2021	infu	Net Revenues External NetRevenuesExternal	102382000	usd
CY2021	infu	Net Revenues Internal NetRevenuesInternal	0	usd
CY2021	us-gaap	Revenues Revenues	102382000	usd
CY2021	us-gaap	Gross Profit GrossProfit	58536000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	55716000	usd
CY2021	us-gaap	Interest Expense InterestExpense	1377000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-186000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1257000	usd
CY2021Q4	us-gaap	Assets Assets	97586000	usd
CY2021	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	15676000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14625000	usd
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1300000	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1200000	usd
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	900000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4600000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3300000	usd
CY2022	us-gaap	Revenues Revenues	109900000	usd
CY2021	us-gaap	Revenues Revenues	102400000	usd
CY2022	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	24400000	usd
CY2021	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	21700000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	49354000	usd
CY2022	us-gaap	Gross Profit GrossProfit	60560000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	44153000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	58906000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	43846000	usd
CY2021	us-gaap	Gross Profit GrossProfit	58536000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40677000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	55716000	usd

Files In Submission

Name	View Source	Status
0001628280-24-015511-index-headers.html	Edgar Link	pending
0001628280-24-015511-index.html	Edgar Link	pending
0001628280-24-015511.txt	Edgar Link	pending
0001628280-24-015511-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
infu-20231231.htm	Edgar Link	pending
infu-20231231.xsd	Edgar Link	pending
infu-20231231xexx211.htm	Edgar Link	pending
infu-20231231xexx231.htm	Edgar Link	pending
infu-20231231xexx232.htm	Edgar Link	pending
infu-20231231xexx311.htm	Edgar Link	pending
infu-20231231xexx312.htm	Edgar Link	pending
infu-20231231xexx321.htm	Edgar Link	pending
infu-20231231xexx322.htm	Edgar Link	pending
infu-20231231xexx971former.htm	Edgar Link	pending
infu-20231231_g1.jpg	Edgar Link	pending
infu-20231231_g2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
infu-20231231_cal.xml	Edgar Link	unprocessable
infu-20231231_def.xml	Edgar Link	unprocessable
infu-20231231_lab.xml	Edgar Link	unprocessable
infu-20231231_pre.xml	Edgar Link	unprocessable
infu-20231231_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INFU
InfuSystem Holdings, Inc Stock $infu

2024 Q2 Form 10-K Financial Statement

#000162828024015511 Filed on April 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INFU InfuSystem Holdings, Inc Stock $infu

2024 Q2 Form 10-K Financial Statement

#000162828024015511 Filed on April 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INFU
InfuSystem Holdings, Inc Stock $infu